Get the Stockscreener App
7.48
10.99%
0.93
After Hours:
7.48
Sensei Biotherapeutics Inc stock is traded at $7.48, with a volume of 44,248.
It is up +10.99% in the last 24 hours and up +5.67% over the past month.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).
See More
Previous Close:
$6.55
Open:
$6.47
24h Volume:
44,248
Relative Volume:
0.34
Market Cap:
$8.24M
Revenue:
-
Net Income/Loss:
$-29.80M
P/E Ratio:
-6.2857
EPS:
-1.19
Net Cash Flow:
$-25.19M
1W Performance:
+11.20%
1M Performance:
+5.67%
6M Performance:
-15.47%
1Y Performance:
-38.60%
1-Day Range:
$6.18
$7.70
1-Week Range:
$5.60
$7.70
52-Week Range:
$5.00
$17.40
Sensei Biotherapeutics Inc Stock (SNSE) Company Profile
Name
Sensei Biotherapeutics Inc
Sector
Industry
Phone
(240) 243-8000
Address
1405 RESEARCH BLVD, SUITE 125, ROCKVILLE
Compare SNSE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNSE
Sensei Biotherapeutics Inc
|
7.48 | 8.24M | 0 | -29.80M | -25.19M | -1.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.37 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
513.54 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.32 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
537.92 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
252.78 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Sensei Biotherapeutics Inc Stock (SNSE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Resumed | H.C. Wainwright | Buy |
| May-14-24 | Initiated | Stephens | Overweight |
| Jul-01-21 | Downgrade | Berenberg | Buy → Hold |
| Jun-29-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-01-21 | Initiated | Berenberg | Buy |
| Mar-01-21 | Initiated | Citigroup | Buy |
| Mar-01-21 | Initiated | Oppenheimer | Outperform |
| Mar-01-21 | Initiated | Piper Sandler | Overweight |
View All
Sensei Biotherapeutics Inc Stock (SNSE) Latest News
Sensei Biotherapeutics (SNSE) Trading Halted Amid Pending News | SNSE Stock News - GuruFocus
Sensei Biotherapeutics Announces 1-for-20 Reverse Stock Split | - GuruFocus
Sensei Biotherapeutics to implement 1-for-20 reverse stock split - Investing.com Australia
Sensei Biotherapeutics to implement 1-for-20 reverse stock split By Investing.com - Investing.com Canada
Sensei Biotherapeutics announces reverse stock split By Investing.com - Investing.com Canada
Sensei Biotherapeutics to Implement 1-for-20 Reverse Stock Split - marketscreener.com
Sensei Biotherapeutics Announces Reverse Stock Split - TipRanks
Sensei Biotherapeutics Sets 1-for-20 Reverse Stock Split - Nasdaq
Sensei Biotherapeutics announces reverse stock split - Investing.com
Sensei Biotherapeutics Announces 1-for-20 Reverse Stock Split | SNSE Stock News - GuruFocus
Sensei Biotherapeutics (SNSE) Announces 1-for-20 Reverse Stock Split | SNSE Stock News - GuruFocus
Sensei Biotherapeutics Announces 1-For-20 Reverse Stock Split - marketscreener.com
Sensei Biotherapeutics Announces 1-for-20 Reverse Stock Split - GlobeNewswire
Sensei Bio's 1:20 Reverse Split Slashes Outstanding Shares from 25M to 1.3MWhat Investors Must Know - Stock Titan
What is HC Wainwright’s Forecast for SNSE Q2 Earnings? - Defense World
Sensei Biotherapeutics (NASDAQ:SNSE) Upgraded at HC Wainwright - Defense World
Sensei Biotherapeutics (SNSE) Receives a 'Buy' Rating from HC Wainwright | SNSE Stock News - GuruFocus
Sensei Biotherapeutics (SNSE) Receives Buy Rating from H.C. Wain - GuruFocus
Sensei Biotherapeutics (SNSE) Receives Buy Rating from H.C. Wainwright | SNSE Stock News - GuruFocus
H.C. Wainwright assumes Buy rating on Sensei Biotherapeutics stock By Investing.com - Investing.com Canada
VISTA Inhibitor Clinical Trials Market Insights and Drug Development Opportunities Report 2025-2028 Featuring Aurigene, Curis, Hummingbird Bioscience, Kineta, PharmAbcine, Sensei BiotherapeuticsResearchAndMarkets.com - FinancialContent
Sensei Biotherapeutics stockholders approve key proposals By Investing.com - Investing.com Nigeria
Sensei Biotherapeutics stockholders approve key proposals - Investing.com
Sensei Biotherapeutics Approves Reverse Stock Split - TipRanks
Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Shares Sold by Renaissance Technologies LLC - Defense World
Sensei Biotherapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Sensei (SNSE) Reports Encouraging Clinical Results in Recent Qua - GuruFocus
Sensei Biotherapeutics Reports Promising Q1 2025 Results - TipRanks
Sensei Biotherapeutics Reports First Quarter 2025 Financial Resu - GuruFocus
Sensei (SNSE) Reports Encouraging Clinical Results in Recent Quarter | SNSE Stock News - GuruFocus
Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress - The Manila Times
Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress | SNSE Stock News - GuruFocus
Sensei Bio's Cancer Drug Achieves Breakthrough: 3X Better Response in PD-L1 Resistant Patients - Stock Titan
Sensei Biotherapeutics Inc expected to post a loss of 22 cents a shareEarnings Preview - TradingView
SEC Form DEF 14A filed by Sensei Biotherapeutics Inc. - Quantisnow
Penny Stocks To Add to Your WatchlistMarch 30th - MarketBeat
Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference - The Manila Times
Promising Penny Stocks To ResearchMarch 29th - MarketBeat
Best Penny Stocks To Follow NowMarch 28th - MarketBeat
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Sensei Biotherapeutics stock hits 52-week low at $0.34 By Investing.com - Investing.com South Africa
Sensei Biotherapeutics stock hits 52-week low at $0.34 - Investing.com
HC Wainwright Reiterates Buy Rating for Sensei Biotherapeutics (NASDAQ:SNSE) - Defense World
Sensei Biotherapeutics (NASDAQ:SNSE) Stock Price Expected to Rise, Oppenheimer Analyst Says - Defense World
Sensei Biotherapeutics (NASDAQ:SNSE) Price Target Raised to $4.00 at Oppenheimer - Armenian Reporter
Sensei Biotherapeutics Reports Promising 2024 Results - TipRanks
Sensei Biotherapeutics (SNSE) Reports Annual Loss and Decline in Cash Reserves - GuruFocus
Sensei stock holds Buy rating, $4 target from H.C. Wainwright By Investing.com - Investing.com Australia
Sensei Rockets on FY ’24 Results - Baystreet.ca
Sensei Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - Marketscreener.com
Sensei Biotherapeutics Reports Favorable Initial Clinical Activity Data For Solnerstotug In Resistant Tumors - Benzinga
Sensei Biotherapeutics Inc Stock (SNSE) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.32%
0.98%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):